Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2023 Nov 9;18(11):e0294382. doi: 10.1371/journal.pone.0294382

Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

Konstantinos Rounis, Dimitrios Makrakis, Chara Papadaki, Alexia Monastirioti, Lambros Vamvakas, Konstantinos Kalbakis, Krystallia Gourlia, Iordanis Xanthopoulos, Ioannis Tsamardinos, Dimitrios Mavroudis, Sofia Agelaki
PMCID: PMC10635507  PMID: 37943834

An additional affiliation is missing for the first author. Konstantinos Rounis is also affiliated with: Laboratory of Translational Oncology, Medical School, University of Crete.

Reference

  • 1.Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, et al. (2021) Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. PloS ONE 16(6): e0252537. doi: 10.1371/journal.pone.0252537 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLOS ONE are provided here courtesy of PLOS

RESOURCES